DBV Technologies S.A.DBVTEarnings & Financial Report
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.
DBVT Q3 2025 Key Financial Metrics
Revenue
$2.8M
Gross Profit
N/A
Operating Profit
$-34.3M
Net Profit
$-33.2M
Gross Margin
N/A
Operating Margin
-1235.7%
Net Margin
-1195.5%
YoY Growth
158.8%
EPS
$-0.24
Financial Flow
DBV Technologies S.A. Q3 2025 Financial Summary
DBV Technologies S.A. reported revenue of $2.8M for Q3 2025, with a net profit of $-33.2M (-1195.5% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $2.8M |
|---|---|
| Net Profit | $-33.2M |
| Gross Margin | N/A |
| Operating Margin | -1235.7% |
| Report Period | Q3 2025 |
DBV Technologies S.A. Annual Revenue by Year
DBV Technologies S.A. annual revenue history includes year-by-year totals (for example, 2024 revenue was $4.2M).
| Year | Annual Revenue |
|---|---|
| 2024 | $4.2M |
| 2023 | $15.7M |
| 2022 | $4.8M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.9M | $1.4M | $1.2M | $1.1M | $511000 | $753000 | $1.5M | $2.8M |
| YoY Growth | 780.0% | -35.9% | -49.3% | -54.8% | -94.2% | -46.5% | 26.2% | 158.8% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $183.0M | $145.9M | $114.2M | $93.1M | $65.7M | $50.6M | $143.4M | $110.5M |
| Liabilities | $42.8M | $34.2M | $35.1M | $39.0M | $38.3M | $47.7M | $57.2M | $57.6M |
| Equity | $140.2M | $111.7M | $79.1M | $54.0M | $27.4M | $2.9M | $86.2M | $52.9M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-13.7M | $-34.7M | $-35.1M | $-22.5M | $-12.3M | $-19.7M | $-33.9M | $-32.4M |
More Companies
ILMN
ILLUMINA, INC.
Revenue
$1.2B
Net Profit
$334.0M
UTHR
UNITED THERAPEUTICS Corp
Revenue
$799.5M
Net Profit
$338.7M
GMAB
GENMAB A/S
Revenue
$925.0M
Net Profit
$336.0M
GH
Guardant Health, Inc.
Revenue
$265.2M
Net Profit
$-92.7M
NBIX
NEUROCRINE BIOSCIENCES INC
Revenue
$805.5M
Net Profit
$153.7M
EXEL
EXELIXIS, INC.
Revenue
$598.7M
Net Profit
$244.5M
MDGL
MADRIGAL PHARMACEUTICALS, INC.
Revenue
$287.3M
Net Profit
$-114.2M
QGEN
QIAGEN N.V.
BMRN
BIOMARIN PHARMACEUTICAL INC
Revenue
$776.1M
Net Profit
$-30.7M
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Revenue
$264.0M
Net Profit
$30.8M